Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities

Video

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how COVID-19 drastically changed his institution and what has been implemented to keep providers and patients safe.

Transcript:

COVID-19 has really changed how we think and how we’ve done everything. We never closed [my institution], but we did a lot of telemedicine visits; we still are, but not as much as before. [COVID-19 has] affected everything from our research program to our patients. Most importantly, it’s affected the patients because we’ve limited visitors for obvious reasons. This has been a harder time for the patients and their loved ones to not have somebody with them when they’re in clinic getting their infusion. We’ve all at this point become accustomed to it. We’re all masked up, I’ve got mine sitting right next to me. It’s just been tough and challenging. We’ve all evolved [but] it’ll be great to get back to normal at some point, though.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
Related Content